Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Propofol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 8/20 | 0.94 |
| ▸ | GABRB1 known ✓ | P18505 | 5/20 | 0.94 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.94 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.94 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.94 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.94 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.94 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.94 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.94 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.94 |
| ▸ | CA1 | P00915 | 2/20 | 0.94 |
| ▸ | CA2 | P00918 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.94 |
| ▸ | LMNA | P02545 | 2/20 | 0.94 |
| ▸ | FAAH | O00519 | 1/20 | 0.94 |
| ▸ | HPGD | P15428 | 1/20 | 0.94 |
| ▸ | TSHR | P16473 | 1/20 | 0.94 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propofol SCHEMBL4135307 | 1.00 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL36245 | 0.97 | GABRA1 (1.00) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL2414429 | 0.97 | GABRA1 (1.00) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL5087474 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL1033835 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL8935177 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL10968616 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL8026569 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL4088686 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL10968613 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101400369-A | Novel colored solutions of injectable drugs and pharmaceutically acceptable salts thereof | WINCH PETER D (US) | 2009-04-01 | — | — | CN | claimed |
| CN-101367834-B | Process for preparing water-soluble phosphonooxymethyl derivatives of alcohols and phenols | MGI GP INC | 2012-04-18 | — | — | CN | disclosed |
| CN-101400369-A | Novel colored solutions of injectable drugs and pharmaceutically acceptable salts thereof | WINCH PETER D (US) | 2009-04-01 | — | — | CN | disclosed |
| CN-101367834-A | Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol | MGI GP INC (US) | 2009-02-18 | — | — | CN | disclosed |
| US-20080214508-A1 | O-phosphonooxymethyl propofol disodium salt; anasthetic, analgesic, anxiolytic agent, antidepressant; bioavailable and pharmacologically active when given by intravenous, than subcutaneous or rectal administration | MGI GP, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| CN-100413508-C | Process for preparing water-soluble phosphonooxymethyl derivatives of alcohols and phenols | GUILFORD PHARM INC (US) | 2008-08-27 | — | — | CN | disclosed |
| US-20070202158-A1 | Methods Of Administering Water-Soluble Prodrugs Of Propofol For Extended Sedation | MGI GP, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| CN-1671395-A | Process for preparing water-soluble phosphonooxymethyl derivatives of alcohols and phenols | GUILFORD PHARM INC (US) | 2005-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214508-A1 | O-phosphonooxymethyl propofol disodium salt; anasthetic, analgesic, anxiolytic agent, antidepressant; bioavailable and pharmacologically active when given by intravenous, than subcutaneous or rectal administration | SI, APC, OPRK1 | GABRA1 791/4885GABRB1 636/4885GABRB2 929/4885 |
| US-20070202158-A1 | Methods Of Administering Water-Soluble Prodrugs Of Propofol For Extended Sedation | SI, GABRP, ALPI | GABRA1 61/4885GABRB1 86/4885GABRB2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.